Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

Dysregulation of Transcription Machinery Drives the Acquisition of BTK Inhibitor and Venetoclax Treatment Resistance in Mantle Cell Lymphoma

Jing Gao, Kevin Qiu, Kallesh Danappa Jayappa, Qing Yin, Michelle Wang, Allen Hu, Danielle C Llaneza, Loryn L Blackburn, Jeffrey W Craig, Bijal D Shah, Craig A. Portell, Michael E Williams, Chongzhi Zang, Jianguo Tao

Blood (2024) 144 (Supplement 1): 6220.

https://doi.org/10.1182/blood-2024-204223

Published: 2024

Journal Articles

Combinatorial Therapy of CDK9 Inhibitor with CD19 CAR-T to Reciprocally Overcome Therapy Resistance and Enhance Treatment Efficacies Against Aggressive B-Cell Lymphomas

Qing Yin, Michelle Wang, Allen Hu, Jing Gao, Danielle C Llaneza, Loryn L Blackburn, Jeffrey W Craig, Bijal D Shah, Craig A. Portell, Michael E Williams, Jianguo Tao

Blood (2024) 144 (Supplement 1): 6219.

https://doi.org/10.1182/blood-2024-204209

Published: 2024

Journal Articles

Molecular Subtyping of DLBCL Patients from the Oncology Research Information Exchange Network

Blood (2024) 144 (Supplement 1): 6199.

https://doi.org/10.1182/blood-2024-204481

Published: 2024

Journal Articles

Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Blood (2024) 144 (Supplement 1): 4501.

https://doi.org/10.1182/blood-2024-199281

Published: 2024

Journal Articles

Durability of Complete Responses in Patients from the ECHELON-3 Study

Blood (2024) 144 (Supplement 1): 3101.

https://doi.org/10.1182/blood-2024-194158

Published: 2024

Journal Articles

Categorization and Impact of Bridging Therapy Prior to CAR T-Cell Infusion in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Pranav Santapuram, Jason T Romancik, Jonathon B Cohen, Melissa Kives, Manali Rupji, Javier Pinilla-Ibarz, Kami J. Maddocks, Craig A. Portell, Joanna M. Rhodes, Brian K. Link

Blood (2024) 144 (Supplement 1): 1744.

https://doi.org/10.1182/blood-2024-204002

Published: 2024

Journal Articles

Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Blood (2024) 144 (Supplement 1): 4489.

https://doi.org/10.1182/blood-2024-200914

Published: 2024

Journal Articles

Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Blood (2024) 144 (Supplement 1): 4483.

https://doi.org/10.1182/blood-2024-200836

Published: 2024

Journal Articles

Overall Survival Following First and Second Relapse of DLBCL Treated with Therapies Including Autologous Transplant and CAR-T Cells: Results from the Lion Prospective Observational Registry

Greg Kirkpatrick, Jeffrey M. Switchenko, Melissa Kives, Katelin Baird, Kami J. Maddocks, Jason T. Romancik, Deborah M. Stephens, Harsh Shah, Javier Pinilla-Ibarz, Julio C Chavez, Matthew Matasar, Craig A. Portell, Michelle Churchman, Jonathon B. Cohen, Umar Farooq, Brian K. Link

Blood (2023) 142 (Supplement 1): 6325.

https://doi.org/10.1182/blood-2023-187198

Published: 2023

Journal Articles

Primary Analysis and Results of Bendamustine, Rituximab, and Venetoclax (BR-VEN) for Initial Treatment of Mantle Cell Lymphoma in Subjects over 60 Years of Age (PrE0405)

Craig A. Portell, Opeyemi Jegede, N. Nora Bennani, Seema Naik, Christopher M. Reynolds, Priyank P. Patel, Michael J. Robertson, Brad S. Kahl

Blood (2023) 142 (Supplement 1): 733.

https://doi.org/10.1182/blood-2023-182374

Published: 2023

Journal Articles

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Yucai Wang, Melissa C. Larson, Steven R. Hwang, Anita Kumar, Ashlee Joseph, Brian T. Hill, Taylor R. Brooks, David A. Bond, Kami J. Maddocks, Alexey Danilov, Christine McCarthy, Jia Ruan, Imran A. Nizamuddin, Brad S. Kahl, Natalie S. Grover, Nazneen B. Khan, Evguenia Ouchveridze, Aung M. Tun, Philip Young, Craig A. Portell, Zoey I. Harris, Javier L. Munoz, Patrick M. Reagan, Georgio Pongas, Izidore S. Lossos, Christine E. Ryan, Reid W. Merryman, Firas Baidoun, Muhamad Alhaj Moustafa, Drew Gerber, Sabarish R. Ayyappan, Brian K. Link, Arash Velayati, Irl Brian Greenwell, Lauren G Banaszak, Priyanka A Pophali, Anthony C. Stack, Marcus R. Messmer, Mayur Narkhede, Amitkumar N. Mehta, Preetesh Jain, Michael L. Wang, Tamara K. Moyo, Nilanjan Ghosh, Rahul S. Bhansali, Stefan K. Barta, Manali K. Kamdar, Jacob Anna, Alexander V. Stanisic, Reem Karmali, Laveniya Kugathasan, Diego Villa, Matthew J. Maurer, James R. Cerhan, Jonathon B. Cohen, Peter Martin

Blood (2023) 142 (Supplement 1): 300.

https://doi.org/10.1182/blood-2023-182942

Published: 2023

Journal Articles

Phase Ib/II Study of Multi-Targeted Therapy with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2023) 142 (Supplement 1): 434.

https://doi.org/10.1182/blood-2023-180173

Published: 2023

Journal Articles

Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: Precog 0404

Jonathon B. Cohen, Opeyemi Jegede, Craig A. Portell, Mehdi Hamadani, Catherine S. Diefenbach, Kevin A. David, Christopher D. Fletcher, Daniel J. Landsburg, Suparna Mantha, Brad S. Kahl

Blood (2022) 140 (Supplement 1): 6487–6488.

https://doi.org/10.1182/blood-2022-164710

Published: 2022

Journal Articles

Nanoliposomal C6-Ceramide Exhibits Synergistic Anti-Cancer Activity with a Small Molecule Agonist of PP2A in Chronic Lymphocytic Leukemia

Kallesh D. Jayappa, Luke R. Vass, Caroline Farrington, Anuradha Illendula, Susan Walker, Michael E. Williams, Craig A. Portell, Todd Fox, Goutham Narla, Mark Kester

Blood (2022) 140 (Supplement 1): 7816–7817.

https://doi.org/10.1182/blood-2022-168086

Published: 2022

Journal Articles

Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL): Preliminary Results from the Embolden Trial

Nathan Roberts, John Lister, N. Nora Bennani, Salvia Jain, Tammy Battaglia, Emily C. Ayers, Craig A. Portell, Michael E. Williams, Prem Batchala, Ipsita Pal, Owen A. O'Connor, John Sanil Manavalan, Enrica Marchi

Blood (2022) 140 (Supplement 1): 9425–9426.

https://doi.org/10.1182/blood-2022-170181

Published: 2022

Journal Articles

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Blood (2022) 140 (Supplement 1): 573–576.

https://doi.org/10.1182/blood-2022-163371

Published: 2022

Journal Articles

Weight Change Trends and Impact of Body Mass Index (BMI) on Outcomes in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma, a Retrospective Analysis from the Lymphoma Innovations Orien Network (LION) Consortium

Yazeed Sawalha, Chenxi Du, Jeffrey M. Switchenko, Melissa Kives, Michelle L. Churchman, Deborah M. Stephens, Javier Pinilla Ibarz, Andrew Matthew Evens, Kami J. Maddocks, Brian K. Link, Jonathon B. Cohen, Craig A. Portell

Blood (2022) 140 (Supplement 1): 11956–11958.

https://doi.org/10.1182/blood-2022-163681

Published: 2022

Journal Articles

Favorable Overall Survival Following First and Second Relapse of MCL with Availability of Novel Therapies: Results from the Lion Prospective Observational Registry

David A. Bond, Jason T. Romancik, Jeffrey M. Switchenko, Brielle Berkowitz, Jonathan R Day, Umar Farooq, Sabarish Ayyappan, Katelin Baird, Michelle L. Churchman, Andrew M. Evens, Bijal D. Shah, Craig A. Portell, Kami J. Maddocks, Brian K. Link, Jonathon B. Cohen, Deborah M. Stephens

Blood (2022) 140 (Supplement 1): 6509–6511.

https://doi.org/10.1182/blood-2022-160306

Published: 2022

Journal Articles

CNS prophylaxis in DLBCL: first do no harm

Craig A. Portell

Blood (2022) 139 (16): 2420–2421.

https://doi.org/10.1182/blood.2022015432

Published: 2022

Journal Articles

Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

Victor Manuel Orellana-Noia, Daniel R. Reed, Ashley Alesia McCook, Jeremy Michael Sen, Christian M. Barlow, Mary-Kate Malecek, Marcus Watkins, Brad S. Kahl, Michael A. Spinner, Ranjana Advani, Timothy J. Voorhees, Anson Snow, Natalie Sophia Grover, Amy Ayers, Jason Romancik, Yuxin Liu, Scott F. Huntington, Julio C. Chavez, Hayder Saeed, Aleksandr Lazaryan, Vikram Raghunathan, Stephen E. Spurgeon, Thomas A. Ollila, Christopher Del Prete, Adam Olszewski, Emily C. Ayers, Daniel J. Landsburg, Benjamin Echalier, Jun Lee, Manali Kamdar, Paolo F. Caimi, Timothy Fu, Jieqi Liu, Kevin A. David, Hanan Alharthy, Jennie Law, Reem Karmali, Harsh Shah, Deborah M. Stephens, Ajay Major, Alexandra E. Rojek, Sonali M. Smith, Amulya Yellala, Avyakta Kallam, Shazi Nakhoda, Nadia Khan, Mohammad Ahsan Sohail, Brian T. Hill, Odeth Barrett-Campbell, Frederick Lansigan, Jeffrey Switchenko, Jonathon Cohen, Craig A. Portell

Blood (2022) 139 (3): 413–423.

https://doi.org/10.1182/blood.2021012888

Published: 2022

Includes: Supplemental data

NARROW

Dysregulation of Transcription Machinery Drives the Acquisition of BTK Inhibitor and Venetoclax Treatment Resistance in Mantle Cell Lymphoma

Combinatorial Therapy of CDK9 Inhibitor with CD19 CAR-T to Reciprocally Overcome Therapy Resistance and Enhance Treatment Efficacies Against Aggressive B-Cell Lymphomas

Molecular Subtyping of DLBCL Patients from the Oncology Research Information Exchange Network

Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Durability of Complete Responses in Patients from the ECHELON-3 Study

Categorization and Impact of Bridging Therapy Prior to CAR T-Cell Infusion in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Overall Survival Following First and Second Relapse of DLBCL Treated with Therapies Including Autologous Transplant and CAR-T Cells: Results from the Lion Prospective Observational Registry

Primary Analysis and Results of Bendamustine, Rituximab, and Venetoclax (BR-VEN) for Initial Treatment of Mantle Cell Lymphoma in Subjects over 60 Years of Age (PrE0405)

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Phase Ib/II Study of Multi-Targeted Therapy with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: Precog 0404

Nanoliposomal C6-Ceramide Exhibits Synergistic Anti-Cancer Activity with a Small Molecule Agonist of PP2A in Chronic Lymphocytic Leukemia

Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL): Preliminary Results from the Embolden Trial

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Weight Change Trends and Impact of Body Mass Index (BMI) on Outcomes in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma, a Retrospective Analysis from the Lymphoma Innovations Orien Network (LION) Consortium

Favorable Overall Survival Following First and Second Relapse of MCL with Availability of Novel Therapies: Results from the Lion Prospective Observational Registry

CNS prophylaxis in DLBCL: first do no harm

Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only